Aoshima M, Nakamura K, Makino I
Second Department of Internal Medicine, Asahikawa Medical College, Japan.
Hokkaido Igaku Zasshi. 1995 Jan;70(1):57-67.
We studied the conjugated bile acid profiles (sulfate, glucuronide, and nonsulfate-nonglucuronide) in serum, urine, and bile of 12 patients with primary biliary cirrhosis (PBC) before and under the ursodeoxycholic acid therapy (UDCA, 600mg/day, 6-8 months). Serum total bile acid concentration in those patients without the UDCA therapy was several times higher than those of healthy volunteers, and the percentage of sulfate to total bile acid was 24.8%. After the UDCA therapy, serum total bile acid concentration increased making a progression of Scheuer's stage. In patients with stage I-III, the percentage of sulfate to total was 13.7-65.0% (32.5%, mean), and that of glucuronide to total was 6.6-43.3% (24.0%). Then, the sum of sulfate and glucuronide conjugates was more than 50% to total. Although in patients with stage IV, serum total bile acid level rose markedly, the percentages of sulfate and glucuronide highly reduced. In urine of patients with stage I-III, a large amount of sulfate and glucuronide was found and the percentage of both conjugates was more than 65% of total. On the other hand, sulfate and glucuronide conjugates were only minor component in bile. Based on these data, we might be led to the following conclusion: (1) in patients with PBC (stage I-III), sulfated conjugates of serum bile acid are not minor component, (2) the increased UDCA in serum of patients with PBC during the UDCA treatment might be more easily extracted into urine as sulfate and glucuronide UDCA.
我们研究了12例原发性胆汁性肝硬化(PBC)患者在熊去氧胆酸治疗(UDCA,600mg/天,6 - 8个月)之前及治疗期间血清、尿液和胆汁中的结合胆汁酸谱(硫酸盐、葡萄糖醛酸苷以及非硫酸盐 - 非葡萄糖醛酸苷)。未接受UDCA治疗的患者血清总胆汁酸浓度比健康志愿者高出数倍,硫酸盐占总胆汁酸的百分比为24.8%。UDCA治疗后,血清总胆汁酸浓度升高,Scheuer分期出现进展。在I - III期患者中,硫酸盐占总的百分比为13.7 - 65.0%(平均32.5%),葡萄糖醛酸苷占总的百分比为6.6 - 43.3%(24.0%)。然后,硫酸盐和葡萄糖醛酸苷结合物的总和占总结合物的比例超过50%。尽管IV期患者血清总胆汁酸水平显著升高,但硫酸盐和葡萄糖醛酸苷的百分比大幅降低。在I - III期患者的尿液中,发现大量的硫酸盐和葡萄糖醛酸苷,两者结合物的百分比超过总结合物的65%。另一方面,硫酸盐和葡萄糖醛酸苷结合物在胆汁中仅为次要成分。基于这些数据,我们可能得出以下结论:(1)在PBC患者(I - III期)中,血清胆汁酸的硫酸化结合物并非次要成分;(2)PBC患者在UDCA治疗期间血清中增加的UDCA可能更容易以硫酸盐和葡萄糖醛酸苷结合的UDCA形式被提取到尿液中。